Sky Labs
Category: AI in Healthcare
South Korean AI healthcare company developing ring-type cuffless continuous blood pressure monitors (CART BP) and a medical data production platform, listing on KOSDAQ in September 2026. Sky Labs was founded in 2015. The company is led by Byunghwan (Jack) Lee. Based in Seongnam, Gyeonggi-do (Pangyo), South Korea. Team size: 101-500. Total funding raised: $40.6M. Latest round: IPO. Key investors include Omron Ventures, IMM Investment, Quad Asset Management, KDB Industrial Bank, Kakao Ventures, Atinum Investment, K2 Investment Partners, Devsisters Ventures, SJG Partners, OpenWater Investment, SparkLabs, Jongno (Jongro) Holdings.
- Founded
- 2015
- Headquarters
- Seongnam, Gyeonggi-do (Pangyo), South Korea
- Team size
- 101-500
- Total funding
- $40.6M
Value proposition
Cuffless ring-type wearable medical devices that measure blood pressure continuously over 24 hours using PPG sensing and proprietary AI algorithms, generating clinically reliable medical data for chronic disease management and clinical trials.
Products and solutions
CART BP pro (hospital outpatient ring BP monitor), CART ON (inpatient), CART BP (personal use), CART-I/CART ONE (heart monitoring wearable), CART O2 (oxygen saturation), CART VITAL (multi-vital: BP, pulse, respiratory rate, body temp, oxygen saturation), CART NET (clinical data platform for RWE and clinical trials).
Unique value
First cuffless continuous blood pressure monitor granted insurance reimbursement in Korea; adopted across all Big Five hospitals and 38 tertiary hospitals; expanding into multi-biosignal monitoring and medical data platform (CART NET).
Target customer
Hospitals and clinics (Big Five hospitals and 38 tertiary general hospitals in Korea), pharmaceutical companies and CROs (via CART NET clinical data platform), and consumers (personal CART BP).
Industries served
Digital health / medical devices, clinical trials and real-world evidence (RWE), medical AI data.
Technology advantage
PPG (photoplethysmography) sensing technology for cuffless 24-hour continuous blood pressure measurement; proprietary AI algorithms for biosignal analysis; CE-MDR certification and Korea MFDS approval; FDA clinical protocol discussions underway.
How they differentiate
Sky Labs is ahead in cuffless blood pressure monitoring by turning a ring into a prescribed medical product used across a large clinical network, with insurance reimbursement and CE-MDR certification, plus a clinical data platform (CART NET) for pharma trials.
Main competitors
VELIA (Switzerland), Aktiia (Switzerland), Biobeat Technologies (Israel), Samsung Electronics Galaxy Ring (adjacent consumer wearable).
Key partnerships
Daewoong Pharmaceutical (exclusive Korea distribution of CART BP / CART ON since 2023), Otsuka Pharmaceutical (exclusive Japan distribution of CART BP pro, signed Feb 2026), OMRON Healthcare / Omron Ventures (strategic investment Nov 2025 + MOU for global BP device collaboration), Korea National Institute of Health (long-term observational cohort studies via CART NET).
Notable customers
All Big Five hospitals in South Korea, 38 of 47 tertiary general hospitals, 1,800+ clinics and hospitals nationwide, Otsuka Pharmaceutical (Japan distribution), OMRON Healthcare.
Major milestones
2015 founded, 2017 Bayer Grants4Apps win, 2021 Series B ₩22.5B, 2023 Series C ₩20.7B, 2025 Omron strategic investment + pre-IPO ₩11.5B at ₩200B valuation, Jun 2026 KOSDAQ preliminary listing approval, Feb 2026 Otsuka exclusive Japan distribution deal, Sep 2026 KOSDAQ listing, FDA approval targeted end-2027.
Growth metrics
H1 2026 revenue ~KRW 5B (~$3.6M), 52% overseas (~KRW 2.6B / ~$1.9M); 2024 revenue ~KRW 4.09B; 2025 revenue ~KRW 7.9B; operating loss ~KRW 14.7B in 2025; 2026 revenue target KRW 10.2B with op. loss ~KRW 15.4B; targeting operating profit in 2028 (KRW 38.7B revenue / KRW 4.7B OP).
Market positioning
Leading Korean digital-health startup in continuous cuffless blood pressure monitoring, expanding from medical devices into a global medical data production platform; targeting FDA approval by end of 2027 for US market entry.
Geographic focus
South Korea (domestic base), Europe/UK (CE-MDR distribution), Japan (Otsuka partnership), and US (FDA approval targeted 2027).
Patents and IP
Not verified publicly.
About Byunghwan (Jack) Lee
Former Samsung Electronics researcher; founded Sky Labs in 2015.
Latest news about Sky Labs
More AI in Healthcare companies
Official website: https://www.skylabs.io
